**Appendix**

Table e-1. Serum natalizumab concentration

|  |  |
| --- | --- |
| **Timepoint** | **Natalizumab Concentrations** (μg/L)(mean±SD)  |
| Baseline | 1.5±2.91 |
| 15 minutes post-dose | 123.9±26.51 |
| Day 2 | 140.6±32.20\* |
| Day 8 | 97.7±21.19 |
| Week 4 | 29.8±17.85 |
| Week 8 | 35.4±25.50 |
| Week 12 | 41.2±30.3 |
| Week 16 | 46.0±35.19 |

\* data available on 12 samples.

Table e-2. Serum natalizumab concentration by age group

|  |  |
| --- | --- |
| **Timepoint** | **Natalizumab Concentrations (μg/L) (mean±SD)** |
| **10-12 years (n=2)** | **13-17 years (n=11)** |
| Baseline | 6±7.25 | 0.7±0.38 |
| 15 minutes post-dose | 115.0±5.66 | 125.5±28.66 |
| Day 2 | 122.9±51.05 | 144.1±29.91\* |
| Day 8 | 87.0±38.18 | 99.7±19.12 |
| Week 4 | 11.4±0.21 | 33.1±17.38 |
| Week 8 | 8.8±11.53 | 40.2±24.52 |
| Week 12 | 10.9±14.41 | 46.7±29.39 |
| Week 16 | 12.0±3.22 | 52.2±34.82 |

SD: Standard deviation. \* data available on 10 samples.

Table e-3. Summary of lymphocyte counts by age group

|  |  |
| --- | --- |
| **Timepoint** | **Lymphocyte count (x109 cells/L) (mean±SD)** |
| **10-12 years (n=2)** | **13-17 years (n=11)** |
| Baseline | 3.00 | 1.74±0.20 |
| Week 4 | 4.53±0.46 | 3.29±0.55 |
| Week 8 | 4.61 | 3.26±0.53 |
| Week 12 | 3.69 | 3.60±0.58 |
| Week 16 | 4.88±0.55 | 3.87±0.78 |